1. Home
  2. RVYL vs PPBT Comparison

RVYL vs PPBT Comparison

Compare RVYL & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ryvyl Inc.

RVYL

Ryvyl Inc.

HOLD

Current Price

$0.28

Market Cap

9.3M

ML Signal

HOLD

Logo Purple Biotech Ltd.

PPBT

Purple Biotech Ltd.

HOLD

Current Price

$0.75

Market Cap

7.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RVYL
PPBT
Founded
2007
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.3M
7.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RVYL
PPBT
Price
$0.28
$0.75
Analyst Decision
Hold
Analyst Count
1
0
Target Price
N/A
N/A
AVG Volume (30 Days)
3.5M
784.3K
Earning Date
11-14-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$48,858,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$297.49
N/A
P/E Ratio
N/A
N/A
Revenue Growth
29.50
N/A
52 Week Low
$0.25
$0.53
52 Week High
$2.33
$5.20

Technical Indicators

Market Signals
Indicator
RVYL
PPBT
Relative Strength Index (RSI) 41.95 45.41
Support Level $0.31 $0.78
Resistance Level $0.35 $0.87
Average True Range (ATR) 0.03 0.06
MACD -0.00 -0.01
Stochastic Oscillator 1.91 17.49

Price Performance

Historical Comparison
RVYL
PPBT

About RVYL Ryvyl Inc.

Ryvyl Inc is a technology company that develops, markets and sells blockchain-based payment solutions, which offers improvements to the payment solutions marketplace. Its focus is developing and monetizing disruptive blockchain-based applications, integrated within an end-to-end suite of financial products, capable of supporting a multitude of industries. Its proprietary, blockchain-based systems are designed to facilitate, record, and store a limitless volume of tokenized assets, representing cash or data, on a secured immutable blockchain-based ledger. It has two reportable segments North America and International. It generates the majority of its revenue from North America.

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.

Share on Social Networks: